GC Biotherapeutics Inc.

GC Biotherapeutics Inc. (GCBT) is the strategic foothold for GC’s business expansion to the North American and European markets. We are building a state of the art bio-manufacturing facility for plasma proteins and will be the only Intravenous Immunoglobulin (IVIG) and Albumin producer in Canada.


Product list

GC Biotherapeutics Inc. (GCBT) will initially manufacture two products: Intravenous Immunoglobulin (IVIG), a key therapeutic solution for the treatment of patients with infectious and immune diseases, and Albumin, used as a blood-volumizing agent.                                                                                     


Contact us

For all inquiries about GC Biotherapeutics Inc., Project Oasis, corporate information, customer relations or about any of our products, click “More” to send us a message.


Recent News


GC Pharma Marks ‘World Hemophilia Day’

YONGIN, South Korea, April 15, 2019 /CNW/ — GC Pharma (formerly known as Green Cross Corporation), a South Korean biopharmaceutical company, joins World... Read More →

Clinigen K.K. and GC Pharma Announce Exclusive Licensing Agreement in Japan for Hunterase (Idursulfase-beta) ICV, Hunter Syndrome Drug

YONGIN, South Korea, April 3, 2019 /CNW/ — Clinigen K.K. and GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280) today... Read More →

A Major Project in Canada

Project Oasis

Project Oasis is a plan to expand GC’s business to North America and Europe. Its Montreal plant will be the project’s focal point. $400 million will be invested in Canada’s only intravenous immunoglobulin (IVIG) and albumin manufacturing plant and in sourcing essential raw materials. We are honoured to receive strategic support from Investissement Quebec and that the Korean National Pension Services has invested in us.


This post is also available in: frFrançais (French)

Back to Top